Akebia Therapeutics Community
NasdaqCM:AKBA Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 31 Fair Values set on narratives written by author
Community Investing Ideas
AN
Consensus Narrative from 5 Analysts
Vafseo And VALOR Study Will Open New Treatment Markets
Key Takeaways Early success of Vafseo and reimbursement coverage expansion likely to drive strong revenue growth and market access. Advancing approval for non-dialysis patients may significantly expand market potential and boost long-term revenue prospects.
View narrativeUS$7.40
FV
49.7% undervalued intrinsic discount21.23%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
17users have followed this narrative
10 days ago author updated this narrative